Alpha 2.0
Login Register
» Articles » PMID: 6110217

Differential Effects of Amphetamine and Neuroleptics on Negative Vs. Positive Symptoms in Schizophrenia

Overview
Journal Psychopharmacology (Berl)
Specialty Pharmacology
Date 1980 Jan 1
PMID 6110217
Citations 32
Authors
B Angrist
J Rotrosen
S Gershon
Affiliations
Soon will be listed here.
Abstract

Positive symptoms of schizophrenia were diminished by neuroleptics and increased by amphetamine and accounted for most of the change seen in the total Brief Psychiatric Rating Scale (BPRS). Negative symptoms in the same subjects were not affected by neuroleptics but increased after amphetamines to a degree that just attained statistical significance. This increase was due to one item (emotional withdrawal) of the negative symptom factor which responded to neuroleptics and amphetamines as did positive symptoms. These findings are discussed with respect to new ideas about the role of dopamine in schizophrenia.

Citing Articles

Mice carrying a schizophrenia-associated mutation of the Arhgap10 gene are vulnerable to the effects of methamphetamine treatment on cognitive function: association with morphological abnormalities in striatal neurons.

Hada K, Wulaer B, Nagai T, Itoh N, Sawahata M, Sobue A Mol Brain. 2021; 14(1):21.

PMID: 33482876 PMC: 7821731. DOI: 10.1186/s13041-021-00735-4.

Lessons learned by giving amphetamine to antipsychotic-medicated schizophrenia patients.

Swerdlow N, Bhakta S, Talledo J, Benster L, Kotz J, Lavadia M Neuropsychopharmacology. 2019; 44(13):2277-2284.

PMID: 31445502 PMC: 6897898. DOI: 10.1038/s41386-019-0495-4.

Patterns of schizophrenia symptoms: hidden structure in the PANSS questionnaire.

Lefort-Besnard J, Varoquaux G, Derntl B, Gruber O, Aleman A, Jardri R Transl Psychiatry. 2018; 8(1):237.

PMID: 30375374 PMC: 6207565. DOI: 10.1038/s41398-018-0294-4.

A Developmental History of the Positive and Negative Syndrome Scale (PANSS).

Liechti S, Capodilupo G, Opler D, Opler M, Yang L Innov Clin Neurosci. 2018; 14(11-12):12-17.

PMID: 29410932 PMC: 5788246.

Prefrontal cortex executive processes affected by stress in health and disease.

Girotti M, Adler S, Bulin S, Fucich E, Paredes D, Morilak D Prog Neuropsychopharmacol Biol Psychiatry. 2017; 85:161-179.

PMID: 28690203 PMC: 5756532. DOI: 10.1016/j.pnpbp.2017.07.004.

References
1.
Spitzer R, Endicott J, Robins E . Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry. 1978; 35(6):773-82. DOI: 10.1001/archpsyc.1978.01770300115013. View
2.
Crow T . Molecular pathology of schizophrenia: more than one disease process?. Br Med J. 1980; 280(6207):66-8. PMC: 1600263. DOI: 10.1136/bmj.280.6207.66. View
3.
Johnstone E, Crow T, Frith C, Carney M, Price J . Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet. 1978; 1(8069):848-51. DOI: 10.1016/s0140-6736(78)90193-9. View
4.
Weinberger D, BIGELOW L, Kleinman J, Klein S, Rosenblatt J, Wyatt R . Cerebral ventricular enlargement in chronic schizophrenia. An association with poor response to treatment. Arch Gen Psychiatry. 1980; 37(1):11-3. DOI: 10.1001/archpsyc.1980.01780140013001. View
5.
Meltzer H, Stahl S . The dopamine hypothesis of schizophrenia: a review. Schizophr Bull. 1976; 2(1):19-76. DOI: 10.1093/schbul/2.1.19. View